PR Newswire Clinical TrialsOriginal article
New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™
Data ReadoutpositiveAdvanceAD-Tx™Positive
AI Analysis
Summary
New study data supports the clinical value of AdvanceAD-Tx™ molecular testing for atopic dermatitis treatment selection, with 94% of surveyed patients interested in molecular guidance. The data highlights unmet need in current systemic therapy approaches.
Outcome Details
Study showed 94% of patients open to systemic therapy expressed interest in molecular testing; more than half of patients on targeted systemic therapies modified treatment due to lack of efficacy
Importance:5/10
Sentiment:
0.60
molecular testingatopic dermatitistreatment selectioncompanion diagnostic
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 24, 2026 8:30 PM